EcoDrugPlus

Phosphoinositide-3-Kinase Regulatory Subunit 5

Ensembl ID : ENSLACG00000003800
Gene Symbol: PIK3R5
3 Cross references
255 Possible Orthologues:

Phospholipase A2 Group Vii

Ensembl ID : ENSLACG00000012246
Gene Symbol: PLA2G7
4 Cross references
203 Possible Orthologues:

Phosphoribosylglycinamide Formyltransferase, Phosphoribosylglycinamide Synthetase, Phosphoribosylaminoimidazole Synthetase

Ensembl ID : ENSLACG00000013824
Gene Symbol: GART
4 Cross references
246 Possible Orthologues:

Plasminogen

Ensembl ID : ENSLACG00000017840
Gene Symbol: PLG
2 Cross references
254 Possible Orthologues:

Plasminogen Activator, Tissue Type

Ensembl ID : ENSLACG00000013211
Gene Symbol: PLAT
4 Cross references
205 Possible Orthologues:

Plasminogen-Like

Ensembl ID : ENSLACG00000002318
Gene Symbol: LOC102356587
2 Cross references
254 Possible Orthologues:

Platelet Activating Factor Receptor

Ensembl ID : ENSLACG00000004778
Gene Symbol: PTAFR
4 Cross references
224 Possible Orthologues:

Platelet Derived Growth Factor Receptor Alpha

Ensembl ID : ENSLACG00000009105
Gene Symbol: PDGFRA
3 Cross references
204 Possible Orthologues:

Platelet Derived Growth Factor Receptor Beta

Ensembl ID : ENSLACG00000014583
Gene Symbol: PDGFRB
3 Cross references
247 Possible Orthologues:

Platelet Derived Growth Factor Subunit B

Ensembl ID : ENSLACG00000002600
Gene Symbol: PDGFB
3 Cross references
261 Possible Orthologues:

Polo Like Kinase 1

Ensembl ID : ENSLACG00000004130
Gene Symbol: PLK1
4 Cross references
189 Possible Orthologues:

Polo Like Kinase 4

Ensembl ID : ENSLACG00000016174
Gene Symbol: PLK4
4 Cross references
215 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).